Arrowhead Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
11analysts covering
FY EPS (est.)
-$3.51next fiscal year
Monitoring Framework
Key Performance Indicators
REDEMPLO (plozasiran) Total Prescriptions Received and In Process Quarterly400.0Target: Sustained commercial growth following U.S. launch
REDEMPLO (plozasiran) Shipped Patients Quarterly180.0Target: Expansion of commercial patient base
Total Cash and Investments Quarterly1.8BTarget: Maintain robust runway to fund 20+ clinical programs
Watch Items
- Plozasiran Phase 3 SHASTA-3 and SHASTA-4 Topline Data in Severe Hypertriglyceridemia (SHTG)Trigger: Topline data readout expected in Q3 2026Action: Evaluate efficacy/safety profile to support planned sNDA submission by year-end 2026
- ARO-MAPT Phase 1 Clinical Data in Tauopathies / Alzheimer's DiseaseTrigger: Interim healthy volunteer data expected in 2H 2026Action: Assess CNS delivery validation and potential platform re-rating
- ARO-DIMER-PA Phase 1/2 Interim Clinical DataTrigger: Interim data expected in 2H 2026 targeting 40-50% reductions in LDL-C and triglyceridesAction: Analyze dual-targeting RNAi efficacy in mixed hyperlipidemia
Research as of 2 Sep 2026